These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 25759406)

  • 21. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
    Schneider J; Schulze G
    Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
    Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
    Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raised CA19-9 and CEA have prognostic relevance in gallbladder carcinoma.
    Sachan A; Saluja SS; Nekarakanti PK; Nimisha ; Mahajan B; Nag HH; Mishra PK
    BMC Cancer; 2020 Aug; 20(1):826. PubMed ID: 32867709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
    Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
    Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
    J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
    Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
    J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer.
    Kim JH; Jun KH; Jung H; Park IS; Chin HM
    Hepatogastroenterology; 2014 May; 61(131):863-9. PubMed ID: 26176088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers.
    Dai H; Liu J; Liang L; Ban C; Jiang J; Liu Y; Ye Q; Wang C
    Respirology; 2014 Jul; 19(5):707-13. PubMed ID: 24903079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor markers in serum and ascites in the diagnosis of benign and malignant ascites.
    Zhu FL; Ling AS; Wei Q; Ma J; Lu G
    Asian Pac J Cancer Prev; 2015; 16(2):719-22. PubMed ID: 25684514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating the probability of cancer with several tumor markers in patients with colorectal disease.
    Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
    Oncology; 2004; 66(4):296-302. PubMed ID: 15218297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series.
    Stotz M; Eisner F; Szkandera J; Absenger G; Kornprat P; Lackner C; Samonigg H; Gerger A; Pichler M
    J Clin Pathol; 2013 Sep; 66(9):753-7. PubMed ID: 23750038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
    Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
    Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracystic concentrations of tumour markers for the diagnosis of cystic liver lesions.
    Fuks D; Voitot H; Paradis V; Belghiti J; Vilgrain V; Farges O
    Br J Surg; 2014 Mar; 101(4):408-16. PubMed ID: 24477793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
    Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
    Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients].
    Grotowski M; Maruszyński M; Piechota W
    Pol Merkur Lekarski; 2001 Dec; 11(66):476-9. PubMed ID: 11899841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S; Shen L; Qian N; Chen K
    Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
    Lucarotti ME; Habib NA; Kelly SB; Rothnie ND; Nelson O; Lindholm L; Cooper MJ; Wood CB; Williamson RC
    Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer.
    Louhimo J; Alfthan H; Stenman UH; Haglund C
    Oncology; 2004; 66(2):126-31. PubMed ID: 15138364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.
    van Manen L; Groen JV; Putter H; Vahrmeijer AL; Swijnenburg RJ; Bonsing BA; Mieog JSD
    Biomarkers; 2020 Mar; 25(2):186-193. PubMed ID: 32009482
    [No Abstract]   [Full Text] [Related]  

  • 40. Better outcomes by monitoring tumour dynamics using sensitive tumour markers in patients with recurrent gastric cancer.
    Komatsu S; Ichikawa D; Nishimura Y; Kubota T; Okamoto K; Shiozaki A; Fujiwara H; Konishi H; Murayama Y; Kuriu Y; Ikoma H; Nakanishi M; Otsuji E
    Anticancer Res; 2013 Apr; 33(4):1621-7. PubMed ID: 23564806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.